Compare PRTA & DIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | DIN |
|---|---|---|
| Founded | 2012 | 1958 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.7M | 425.3M |
| IPO Year | 2013 | 1994 |
| Metric | PRTA | DIN |
|---|---|---|
| Price | $9.27 | $29.54 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 7 |
| Target Price | $19.00 | ★ $29.00 |
| AVG Volume (30 Days) | ★ 312.7K | 199.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.78% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.26 | ★ 0.92 |
| Revenue | $814,000.00 | ★ $879,300,000.00 |
| Revenue This Year | $1,111.38 | $3.61 |
| Revenue Next Year | N/A | $0.64 |
| P/E Ratio | $36.69 | ★ $33.54 |
| Revenue Growth | N/A | ★ 8.25 |
| 52 Week Low | $7.73 | $22.85 |
| 52 Week High | $11.80 | $39.68 |
| Indicator | PRTA | DIN |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 27.04 |
| Support Level | $9.05 | $28.05 |
| Resistance Level | $9.36 | $30.32 |
| Average True Range (ATR) | 0.35 | 1.20 |
| MACD | 0.01 | -0.50 |
| Stochastic Oscillator | 44.40 | 6.18 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.